טוען...
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
BACKGROUND: Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular events. Comparative effectiveness of these new antidiabetic drug classes remains unclear. We therefore performed a network met...
שמור ב:
| הוצא לאור ב: | Cardiovasc Diabetol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6714383/ https://ncbi.nlm.nih.gov/pubmed/31462224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0916-z |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|